Sun Pharmaceutical Industries Limited has announced the schedule for its upcoming analyst and institutional investor meetings in June 2026. The company will participate in three major conferences, including the BofA India Conference-2026, Morgan Stanley's India Investment Forum 2026, and Citi India Conference 2026. All interactions are set to take place in Mumbai.

The meetings will feature both group and one-on-one sessions, conducted physically. The company clarified that it will not disclose any Unpublished Price Sensitive Information (UPSI) during these interactions. Additionally, the schedule remains subject to change due to exigencies on either side.

Meeting Schedule

Sun Pharmaceutical Industries announced updated results from the pivotal CK-301-101 trial of UNLOXCYT (cosibelimab-ipdl) for locally advanced cutaneous squamous cell carcinoma (laCSCC) at the ASCO 2026 Annual Meeting. The data, presented on May 31, 2026, in Chicago, demonstrated a 50% objective response rate in 64 patients, with 27% achieving a complete response and 23% a partial response. The median duration of response was not reached over a median follow-up of 31 months, indicating durable clinical efficacy.

The study cohort consisted of patients with a median age of 77 years, 66% of whom were male, reflecting the typical clinical population for this disease. Patients received a median of 29 doses over a median treatment duration of 60 weeks. The safety profile was described as manageable, with treatment-emergent adverse events reported in 95% of patients, though none were fatal. Grade ≥3 treatment-emergent adverse events were reported in 41% of patients and considered treatment-related in 11%.

Efficacy and Safety Data

The investigator-reviewed data highlighted clinically meaningful efficacy alongside a tolerable safety profile. Immune-related adverse reactions were observed in 34% of patients, with Grade ≥3 events occurring in only one patient (2%). The most common adverse events were anemia and diarrhea, each recorded in 27% of patients.

Presentation Details

The poster presentation, titled "Efficacy and safety of cosibelimab 800 mg every 2 weeks for locally advanced cutaneous squamous cell carcinoma: Updated follow-up from a pivotal study," was part of the Melanoma/Skin Cancers session. Dr. Rahul Ladwa, a study co-author, presented the findings. The study represents the second largest prospective study of laCSCC patients treated with PD-(L)1 monotherapy.

UNLOXCYT is indicated for the treatment of adults with metastatic CSCC or laCSCC who are not candidates for curative surgery or curative radiation. The recommended dosage is 1,200 mg as an intravenous infusion over 60 minutes every 3 weeks. The company noted that the 1,200 mg Q3W regimen provides similar overall exposure and PD-L1 receptor coverage as the 800 mg Q2W trial regimen used in the study.

Analyst View: Citi Maintains Buy Rating

Building on the strength of the ASCO 2026 clinical data, Citi has maintained a Buy rating on Sun Pharmaceutical Industries with a target price of ₹2180. The brokerage cited the strong ASCO 2026 data as reinforcing UNLOXCYT's competitive positioning in the laCSCC market, along with improved confidence in the drug's efficacy and tolerability profile. Citi's assessment supports expectations of $400m+ peak sales by FY30 for UNLOXCYT.